Products for Research Use Only

Sparfosic acid

CAT: 0804-HY-112732-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112732-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines[1][2][3].
CAS Number
51321-79-0
UNSPSC
12352211
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/sparfosic-acid.html
Purity
99.33
Solubility
H2O : ≥ 100 mg/mL
Smiles
O=C(O)C[C@@H](C(O)=O)NC(CP(O)(O)=O)=O
Molecular Formula
C6H10NO8P
Molecular Weight
255.12
References & Citations
[1]Wang J, et al. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug;47 (2) :782-90.|[2]Angela D. Morris, et al. A New, Efficient, Two Step Procedure for the Preparation of the Antineoplastic Agent Sparfosic Acid.|[3]Johnson RK, et al. Antitumor activity of N- (phosphonacetyl) -L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 1976;36 (8) :2720-2725.|[4]Wadler S, et al. Phase II trial of N- (phosphonacetyl) -L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Eur J Cancer. 1996;32A (7) :1254-1256.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Nat Commun. 2024 Feb 16;15 (1) :1442.|Res Sq. 2025 Sep 14.|bioRxiv. 2023 Aug 3.|Nat Metab. 2025 Nov 13.

Popular Products